Sangamo Therapeutics (SGMO) Net Margin (2016 - 2025)
Sangamo Therapeutics (SGMO) has disclosed Net Margin for 16 consecutive years, with 263.0% as the latest value for Q4 2025.
- For Q4 2025, Net Margin rose 9694.0% year-over-year to 263.0%; the TTM value through Dec 2025 reached 310.81%, down 13596.0%, while the annual FY2025 figure was 310.81%, 14136.0% down from the prior year.
- Net Margin hit 263.0% in Q4 2025 for Sangamo Therapeutics, up from 6012.05% in the prior quarter.
- Across five years, Net Margin topped out at 18.99% in Q3 2024 and bottomed at 10205.61% in Q1 2024.
- Average Net Margin over 5 years is 1814.9%, with a median of 200.89% recorded in 2022.
- Year-over-year, Net Margin tumbled -1021899bps in 2024 and then surged 1003914bps in 2025.
- Sangamo Therapeutics' Net Margin stood at 166.96% in 2021, then dropped by -14bps to 190.87% in 2022, then plummeted by -1447bps to 2952.74% in 2023, then surged by 88bps to 359.94% in 2024, then increased by 27bps to 263.0% in 2025.
- According to Business Quant data, Net Margin over the past three periods came in at 263.0%, 6012.05%, and 109.18% for Q4 2025, Q3 2025, and Q2 2025 respectively.